Show simple item record

Why have transgenic rodent models failed to successfully mimic Alzheimer’s disease. How can we develop effective drugs without them?

dc.contributor.authorFranco, R.
dc.contributor.authorMartínez Pinilla, Eva 
dc.contributor.authorNavarro, G.
dc.date.accessioned2019-08-21T07:34:05Z
dc.date.available2019-08-21T07:34:05Z
dc.date.issued2019
dc.identifier.citationExpert Opinion on Drug Discovery, 14(4), p. 327-330 (2019); doi:10.1080/17460441.2019.1581169
dc.identifier.issn1746-0441
dc.identifier.urihttp://hdl.handle.net/10651/52220
dc.format.extentp. 327-330
dc.language.isoeng
dc.relation.ispartofExpert Opinion on Drug Discovery, 14
dc.rights© 2019 Informa UK Limited, trading as Taylor & Francis Group
dc.rightsCC Reconocimiento - No comercial - Sin obras derivadas 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScopus
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85062969477&doi=10.1080%2f17460441.2019.1581169&partnerID=40&md5=e63fe55248a5a2396fa977bee3031438
dc.titleWhy have transgenic rodent models failed to successfully mimic Alzheimer’s disease. How can we develop effective drugs without them?
dc.typejournal article
dc.identifier.doi10.1080/17460441.2019.1581169
dc.relation.publisherversionhttp://dx.doi.org/10.1080/17460441.2019.1581169
dc.rights.accessRightsopen access
dc.type.hasVersionAM


Files in this item

untranslated

This item appears in the following Collection(s)

Show simple item record

© 2019 Informa UK Limited, trading as Taylor & Francis Group
This item is protected with a Creative Commons License